There are 2789 resources available
419P - XELOX/XELIRI alternative regimen as first-line treatment of metastatic colorectal cancer (CCRCTO-2: TROT): A phase II study
Presenter: YU HAN
Session: ePoster Display
264P - AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)
Presenter: Sarat Chandarlapaty
Session: ePoster Display
423P - From clinical trial to bedside: Triplet chemotherapy (FOLFOXIRI-B) in metastatic colorectal cancer
Presenter: Guus Bol
Session: ePoster Display
425P - Cetuximab could be administered once every two weeks instead of once weekly
Presenter: sarah Lobet
Session: ePoster Display
426P - Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
Presenter: Augusto Valdivia
Session: ePoster Display
427P - Real world data of trifluridine/tipiracil in refractory mCRC: A multicenter experience at four GEODA Spanish hospitals
Presenter: Julia Martinez Perez
Session: ePoster Display
428P - Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer
Presenter: Hong Qiu
Session: ePoster Display
Resources:
Abstract